Table 3.
Comparative analysis of regional quota agreements for TNF⍺ inhibitors, based on information available on the websites of the 17 German PA regions [31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47]. Quotas were set either generally for biosimilars or more specifically for the therapeutic group or for each of the active substances within the therapeutic group. Quotas may apply to all prescribers or to specific medical specialties.
| Quota Agreements: Characteristics | ||||||
|---|---|---|---|---|---|---|
| Regions | Early Quota Adoption: (Before 2016) |
Set Unspecifically for Biosimilars | Set for the Category of TNFα Inhibitors | Set for the Active Substance | Applied Generally to All Prescribers | Applied Differently per Specialty |
| Baden-Württemberg | √ | √ | ||||
| Bavaria | √ | √ | √ | |||
| Berlin | √ | √ | ||||
| Brandenburg | √ | √ | ||||
| Bremen | √ | √ | ||||
| Hamburg | √ | √ | ||||
| Hesse | √ | √ | ||||
| Mecklenburg Western Pomerania: (missing data) |
||||||
| Lower Saxony | √ | √ | √ | |||
| Northrhine | √ | √ | ||||
| Rhineland Palatinate | √ | √ | ||||
| Saarland | √ | √ | ||||
| Saxony | √ | √ | ||||
| Saxony-Anhalt | √ | √ | ||||
| Schleswig Holstein | √ | √ | ||||
| Thuringia | √ | √ | ||||
| Westphalia- Lippe | √ | √ | √ | |||